US Supreme Court rules against effort to restrict access to abortion pill mifepristone

The U.S. Supreme Court Thursday rejected a bid by anti-abortion groups and doctors to restrict access to the abortion pill.

The U.S. Supreme Court Thursday rejected a bid by anti-abortion groups and doctors to restrict access to the abortion pill. (Evelyn Hockstein, Reuters)


4 photos
Save Story
Leer en español

Estimated read time: 4-5 minutes

WASHINGTON — The U.S. Supreme Court rejected a bid by anti-abortion groups and doctors to restrict access to the abortion pill, handing a victory on Thursday to President Joe Biden's administration in its efforts to preserve broad access to the drug.

The justices, two years after ending the recognition of a constitutional right to abortion, ruled in a 9-0 decision authored by conservative Justice Brett Kavanaugh to overturn a lower court's decision to roll back Food and Drug Administration steps in 2016 and 2021 that eased how the drug, called mifepristone, is prescribed and distributed.

The pill, given FDA regulatory approval in 2000, is used in more than 60% of U.S. abortions.

The court ruled that the plaintiffs behind the lawsuit challenging mifepristone lacked the necessary legal standing to pursue the case, which required that they show they have been harmed in a way that can be traced to the FDA.

Kavanaugh wrote that even though the plaintiffs do not prescribe or use mifepristone, they want the FDA to make it harder for other doctors to prescribe it and women to receive it.

"Under Article III of the Constitution, a plaintiff's desire to make a drug less available for others does not establish standing to sue," Kavanaugh wrote.

That provision of the Constitution lays out the authority of the judicial branch of the U.S. government.

A ruling in favor of the plaintiffs could have threatened the regulatory authority of the FDA over drug safety.

The plaintiffs targeted FDA regulatory actions in 2016 and 2021, including allowing for medication abortions at up to 10 weeks of pregnancy instead of seven, and for mail delivery of the drug without a woman first seeing a clinician in-person. The suit initially had sought to reverse FDA approval of mifepristone, but that aspect was rebuffed by a lower court.

The case represented another front in the intensifying battle over abortion rights in the United States. The Supreme Court, which has a 6-3 conservative majority, in 2022 overturned its 1973 Roe v. Wade precedent that had legalized abortion nationwide, prompting numerous states to enact Republican-backed measures banning or sharply restricting the procedure.

Biden, seeking a second term in office in the Nov. 5 U.S. election, is an outspoken advocate for abortion rights. He and his fellow Democrats have sought to make abortion rights a central theme against Republicans ahead of the election.

Abortion rights advocates and Democratic lawmakers expressed relief at the decision, but also concern that the Supreme Court had entertained the case in the first place.

U.S. Senate Majority Leader Chuck Schumer, a Democrat, said that "no one should be celebrating this decision. We are not yet out of the woods."

The mifepristone dispute is not the only abortion case the Supreme Court is due to decide during this presidential election year. It also is expected to rule by the end of June on the legality of Idaho's strict Republican-backed abortion ban that forbids terminating a pregnancy even if necessary to protect the health of a pregnant woman facing a medical emergency.

The fight over mifepristone

Mifepristone is taken with another drug called misoprostol to perform medication abortions.

The FDA has said that after decades of use by millions of women in the United States and around the world, mifepristone has proven "extremely safe" and that studies have demonstrated that "serious adverse events are exceedingly rare."

The plaintiffs, led by the Alliance for Hippocratic Medicine, argued that the FDA acted contrary to its mandate to ensure medications are safe when it eased the restrictions on mifepristone. The plaintiffs accused the FDA of violating a federal law governing the actions of regulatory agencies.

The plaintiffs sued in Texas in 2022. U.S. District Judge Matthew Kacsmaryk broadly sided with them in a 2023 decision that would have effectively pulled the pill off the market.

After the administration appealed, the New Orleans-based 5th U.S. Circuit Court of Appeals did not go as far as Kacsmaryk but still ruled against the FDA's decisions in 2016 and 2021 widening access to the pill. The 5th Circuit's ruling was placed on hold pending the Supreme Court's review.

In a May Reuters/Ipsos poll, 50% of respondents said they supported an in-person doctor visit requirement for abortion medication, while 33% said they opposed that rule. Seventeen percent said they were unsure.

Some 57% of respondents in the poll said abortion should be legal in all or most cases, up from 46% in Reuters/Ipsos polls conducted in 2014. Some 31% of respondents in the latest poll said it should be illegal in most or all cases, down from 43% in 2014 polls. About 10% of respondents consistently say they are not sure.

The Supreme Court heard arguments in the mifepristone case in March.

The case marked the first time any court had second-guessed the FDA's expertise and judgment to restrict access to an approved drug, according to Biden's administration.

Photos

Related stories

Most recent Police & Courts stories

Related topics

LifestylePolice & CourtsPolitics
Andrew Chung

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast